Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine orally disintegrating film plus cognitive rehabilitation for type 2 diabetes with amnestic mild cognitive impairment
ChiCTR2600135955Phase 4Recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of memantine in Mild Cognitive Impairment (MCI) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Second Hospital of Shandong University. Primary endpoints: Emotional state, Sleep quality and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
memantine
03
Conditions
Mild Cognitive Impairment (MCI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600135955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135955.